Moreover, we postulate that the MEK/ERK-FAM83A feed-forward loop may be a novel therapeutic target in pancreatic cancer cells, including those that remain dependent on mutant RAS, as well as those that are independent of mutant RAS. This evidence concerns the gene MAP2K7 and familial pancreatic carcinoma.